IC
AMED

Innealta Capital’s Amedisys AMED Stock Holding History

Innealta Capital’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-701
Closed -$64.4K – 221
2024
Q2 		$64.4K Buy
+701
New +$65K 0.02% 308

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Innealta Capital's AMED Position: Q3 2024 in Review

Innealta Capital sold out of Amedisys (AMED) in Q3 2024, closing a stake of 701 shares — an estimated $64.4K sold.

Innealta Capital first reported a position in AMED in Q2 2024 and held it in 1 quarter. The position peaked at $64.4K in Q2 2024. 285 funds tracked by Wall St. Rank hold AMED as of Q3 2024.

  • Innealta Capital reported no remaining Amedisys position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 701 Amedisys shares in Q3 2024, an estimated $64.4K.
  • Innealta Capital first reported a position in Amedisys in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Amedisys position peaked at $64.4K in Q2 2024.
  • 285 funds tracked by Wall St. Rank held Amedisys as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.